Rogue calcium in the bloodstream can have a detrimental impact on health. For example, when calcium deposits in arteries, it causes them to stiffen, impairing blood flow and increasing cardiovascular risks. Yet rapidly surfacing evidence connects soft-tissue calcification to other systems’ deterioration, including the lungs, brain, vision and more, highlighting the potential impact Vitamin K2 can have on keeping calcification at bay.
Vitamin K2 is the only compound to date clinically shown to impact calcification by activating a specific K-dependent protein already present in the body. While interventional studies with cardiovascular endpoints have proven this, new research demonstrates how this mechanism could play an essential role in supporting full-body health – not only as a standalone ingredient, but when formulated in tandem with complementary nutrients, such as Vitamin D3 and Omega-3s. Of note is K2’s role in creating a strong foundation of health that arms the population to be better equipped to face COVID-19.
All of this evidence lends itself to the argument that correcting a widespread Vitamin K2 deficiency can greatly impact global health. The first step in correcting that deficiency is establishing a Vitamin K2-specific recommended daily intake.
Register for this webinar to gain:
- An understanding of the detrimental role calcification plays in the cardiovascular system and various other systems
- Insight into the latest Vitamin K2 research developments
- A unique perspective on Vitamin K2’s enhanced role during COVID-19
- Clear considerations for formulating Vitamin K2 with other essential nutrients that provide multi-system health support
- Important criteria for raw material selection
Katarzyna Maresz, PhD, President, International Science and Health Foundation
Katarzyna Maresz holds a PhD in Biological Sciences from the Medical Faculty of the Jagiellonian University, Poland, and practiced at the Laboratory of Cellular and Molecular Immunology, Blood Research Institute in Milwaukee, WI, USA. Having published more than 30 scientific papers, she is involved in clinical trials with Vitamin K2 in Poland and Europe, cooperating with many research centers regarding K2 health effects and mechanism of action. She has published peer-reviewed papers in the K2 field and presented at scientific meetings. Dr. Maresz is currently the president of the International Science and Health Foundation and the scientific coordinator of the educational portal VitaminK2.org.Message Presenter
Anne Roksvåg, NattoPharma ASA Senior Marketing Manager
With a background in international marketing and nutritional therapy, Anne Roksvåg has more than 10 years of experience holding various product and marketing management positions within the food and nutraceuticals industry, ranging from technical know-how to crafting marketing campaigns. She champions the understanding that Vitamin K2 is a “Better Together” ingredient that enhances other vital nutrients when combined in a supplement that aims to support lifelong health. Aiding NattoPharma’s B2B customers to resonate with today’s health-conscious consumer, Roksvåg is a critical contributor in conceptualizing product formulations with vitamin K2 for different demographics.Message Presenter
Who Should Attend?
- Product Development/Management
- Research and Development
- New Business Initiatives/Business Development
- Chief Science Officers
- Purchasing/Sourcing Managers
- Quality Managers
What You Will Learn
In this webinar, participants will:
- Learn about the dangerous influence that soft tissue calcification has on human health
- Get an in-depth perspective on the new research confirming how the K2 mechanism impacts other systems beyond bone and cardiovascular health
- Discover unique and innovative formulation opportunities where Vitamin K2 can enhance the impact of established core nutrients
- Learn the essential considerations for selecting the right Vitamin K2 ingredient for their brand
As the world leader in Vitamin K2 Research and Development, NattoPharma has invested heavily in in-vitro, in-vivo, and clinical studies to substantiate and document the efficacy of its flagship brand, MenaQ7® Vitamin K2 as MK-7. To date, the company has 20 human clinical trials published in respected peer-reviewed journals, with even more underway. This commitment has created the only clinically validated and patented Vitamin K2 on the market. NattoPharma is fully committed to educating consumers and practitioners about the nutritional benefits of Vitamin K2, and to providing the highest quality raw material to the marketplace so manufacturers can create products that deliver on the promise of improving health. Based in Norway, NattoPharma has a global presence – establishing its North American subsidiary, NattoPharma USA, Inc., in East Brunswick, NJ, and NattoPharma R&D Ltd. in Cyprus. For more information visit www.nattopharma.com and www.menaq7.com.